{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:50:47Z","timestamp":1787161847839,"version":"build-2736575974"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the effectiveness of topical clascoterone (TC) compared to oral spironolactone for acne vulgaris treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A computerized search through PubMed\/MEDLINE, SCOPUS, and the Cochrane Library was conducted to find relevant papers. We used the \"netmeta\" and \"meta\" packages for network meta-analysis (NMA) in RStudio 1.2.5019 (2009\u20132019 RStudio, Inc.) to conduct all of our statistical tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven articles (n = 2,006 patients) were included. The fixed-effect size showed that TC 1% bis in die (BID) showed potential effectiveness in reducing the inflammatory and non-inflammatory lesion count compared to placebo (Standardized mean difference, SMD = -0.27, 95% CI: -0.36 to -0.17) and (SMD = -0.31, 95% CI: -0.41 to -0.22), respectively. The random-effect size showed that TC 1% BID was significantly associated with a 12-week treatment success compared to placebo (Odds ratio, OR = 2.44, 95% CI: 1.12 to 5.30). Spironolactone 200 mg was associated with a significant reduction in total lesion count (SMD = -4.46, 95% CI: -5.60 to -3.32).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TC appears to reduce both inflammatory and non-inflammatory lesion count and may lead to treatment success. Spironolactone at 200 mg showed potential effectiveness in terms of total lesion count reduction. These results suggest that both TC and Spironolactone could be beneficial in treating patients with acne vulgaris.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0298155","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:32:16Z","timestamp":1717075936000},"page":"e0298155","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9590-322X","authenticated-orcid":true,"given":"Mohammad A.","family":"Basendwh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer Abdulaziz","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abdulla","family":"Bukhamsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf Abdulrashid","family":"Abdulwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abdullah","family":"Alaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"pone.0298155.ref001","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1610-0387.2007.06274.x","article-title":"Pathophysiology of acne.","volume":"5","author":"K Degitz","year":"2007","journal-title":"J der Dtsch Dermatologischen Gesellschaft = J Ger Soc Dermatology JDDG."},{"key":"pone.0298155.ref002","first-page":"99","article-title":"[How acne vulgaris develops].","volume":"61","author":"G. Plewig","year":"2010","journal-title":"Hautarzt"},{"key":"pone.0298155.ref003","volume-title":"Andrew\u2019s diseases of the skin E-book: clinical dermatology","author":"WD James","year":"2011"},{"key":"pone.0298155.ref004","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.12149","article-title":"Epidemiology of acne vulgaris","volume":"168","author":"K Bhate","year":"2013","journal-title":"Br J Dermatol"},{"key":"pone.0298155.ref005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjd.13462","article-title":"A global perspective on the epidemiology of acne","volume":"172","author":"JKL Tan","year":"2015","journal-title":"Br J Dermatol"},{"key":"pone.0298155.ref006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bjd.20882","article-title":"Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019*","volume":"186","author":"H Chen","year":"2022","journal-title":"Br J Dermatol"},{"key":"pone.0298155.ref007","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/bjd.13786","article-title":"Cumulative mental health consequences of acne: 23-year follow-up in a general population birth cohort study","author":"S Ramrakha","year":"2016","journal-title":"The British journal of dermatology"},{"key":"pone.0298155.ref008","first-page":"527","article-title":"Evaluating hyperandrogenism: a challenge in acne management.","volume":"7","author":"JC Harper","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"pone.0298155.ref009","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-012-1265-x","article-title":"The role of androgen and androgen receptor in skin-related disorders","volume":"304","author":"J-J Lai","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"pone.0298155.ref010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"AL Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"pone.0298155.ref011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20198203","article-title":"Adult female acne: a guide to clinical practice.","volume":"94","author":"E Bagatin","year":"2019","journal-title":"An Bras Dermatol."},{"key":"pone.0298155.ref012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.","volume":"18","author":"AM Layton","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"pone.0298155.ref013","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro.","volume":"18","author":"C Rosette","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"pone.0298155.ref014","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1039\/C4MD00049H","article-title":"A full conformational characterization of antiandrogen cortexolone-17\u03b1-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopy","volume":"5","author":"P Ferraboschi","year":"2014","journal-title":"Medchemcomm"},{"key":"pone.0298155.ref015","first-page":"563","article-title":"Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study.","volume":"18","author":"A Mazzetti","year":"2019","journal-title":"J Drugs Dermatol."},{"key":"pone.0298155.ref016","first-page":"881","article-title":"Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist.","volume":"54","author":"G Celasco","year":"2004","journal-title":"Arzneimittelforschung."},{"key":"pone.0298155.ref017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"B Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"pone.0298155.ref018","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"VA Welch","year":"2019"},{"key":"pone.0298155.ref019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","article-title":"Cortexolone 17\u03b1-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0\u00b705% cream","volume":"165","author":"V Trifu","year":"2011","journal-title":"Br J Dermatol"},{"key":"pone.0298155.ref020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","volume":"111","author":"A Goodfellow","year":"1984","journal-title":"Br J Dermatol"},{"key":"pone.0298155.ref021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","volume":"115","author":"MF Muhlemann","year":"1986","journal-title":"Br J Dermatol"},{"key":"pone.0298155.ref022","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1610-0387.2008.06741.x","article-title":"Topical retinoids in acne\u2014an evidence-based overview.","volume":"6","author":"A Thielitz","year":"2008","journal-title":"J der Dtsch Dermatologischen Gesellschaft = J Ger Soc Dermatology JDDG."},{"key":"pone.0298155.ref023","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.","volume":"156","author":"A Hebert","year":"2020","journal-title":"JAMA dermatology"},{"key":"pone.0298155.ref024","first-page":"570","article-title":"A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.","volume":"18","author":"A Mazzetti","year":"2019","journal-title":"J Drugs Dermatol."},{"key":"pone.0298155.ref025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/CCID.S114830","article-title":"Hormonal treatment of acne vulgaris: an update.","volume":"9","author":"ML Elsaie","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"pone.0298155.ref026","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004425.pub5","article-title":"Combined oral contraceptive pills for treatment of acne.","volume":"CD004425","author":"AO Arowojolu","year":"2012","journal-title":"Cochrane database Syst Rev."},{"key":"pone.0298155.ref027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1684\/ejd.2017.3062","article-title":"Adult female acne treated with spironolactone: a retrospective data review of 70 cases","volume":"27","author":"A Isvy-Joubert","year":"2017","journal-title":"Eur J Dermatol"},{"key":"pone.0298155.ref028","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.det.2015.11.005","article-title":"Use of Oral Contraceptives for Management of Acne Vulgaris: Practical Considerations in Real World Practice.","volume":"34","author":"JC Harper","year":"2016","journal-title":"Dermatol Clin."},{"key":"pone.0298155.ref029","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne","volume":"151","author":"M Plovanich","year":"2015","journal-title":"JAMA Dermatology"},{"key":"pone.0298155.ref030","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/1346-8138.15559","article-title":"Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double-blind, placebo-controlled trial","volume":"47","author":"M Patiyasikunt","year":"2020","journal-title":"J Dermatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:32:45Z","timestamp":1717075965000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298155"}},"subtitle":[],"editor":[{"given":"Kaisar","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298155","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}